Benitec Biopharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Benitec Biopharma Ltd ADR (BNTC)
Benitec Biopharma Ltd ADR stock price live, this page displays NASDAQ BNTC stock exchange data. View the BNTC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Benitec Biopharma Ltd ADR real time stock price chart below.
What Is the Benitec Biopharma Ltd ADR Stock Price Today?
The Benitec Biopharma Ltd ADR stock price today is 13.060.
What Is the Stock Symbol for Benitec Biopharma Ltd ADR?
The stock symbol for Benitec Biopharma Ltd ADR is "BNTC."
What Stock Exchange Does Benitec Biopharma Ltd ADR Trade On?
Benitec Biopharma Ltd ADR is listed and trades on the NASDAQ stock exchange.
Is Benitec Biopharma Ltd ADR a Good Stock to Buy?
Determining whether Benitec Biopharma Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BNTC quote. (ISIN: US08205P2092)
What Is the Benitec Biopharma Ltd ADR Stock Price Today?
The Benitec Biopharma Ltd ADR stock price today is 13.060.
What Is the Stock Symbol for Benitec Biopharma Ltd ADR?
The stock symbol for Benitec Biopharma Ltd ADR is "BNTC."
What Stock Exchange Does Benitec Biopharma Ltd ADR Trade On?
Benitec Biopharma Ltd ADR is listed and trades on the NASDAQ stock exchange.
Is Benitec Biopharma Ltd ADR a Good Stock to Buy?
Determining whether Benitec Biopharma Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BNTC quote. (ISIN: US08205P2092)
NASDAQ
Currency in USD
13.060
+0.370(+2.92%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.710
13.325
52 wk Range
9.850
16.760
BNTC is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.71013.325
52 wk Range
9.85016.760
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BNTC Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
24.167
Upside
+85.04%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Form 4 Benitec Biopharma Ltd ADR For: 30 June- Investing.com
Form 8K Benitec Biopharma Ltd ADR For: 14 May- Investing.com
Benitec Biopharma receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Benitec Biopharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 4 Benitec Biopharma Ltd ADR For: 30 June
- Investing.com
- Benitec Biopharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 24.167
(+85.04% Upside)
Benitec Biopharma Ltd ADR SWOT Analysis
Clinical Breakthrough | Benitec's BB-301 gene therapy for OPMD achieved a remarkable 100% response rate in low-dose trials, positioning the company for potential FDA approval with promising efficacy signals. |
Regulatory Edge | Discover how Fast Track and Orphan Drug designations from FDA and EMA provide Benitec strategic advantages, potentially accelerating the path to market for its innovative OPMD treatment. |
Financial Outlook | With a $30 million capital raise and analyst price targets averaging $20.50, Benitec demonstrates investor confidence despite broader negative sentiment in the gene therapy sector. |
Technological Advantage | Explore Benitec's proprietary ddRNAi "silence and replace" platform, offering localized gene therapy that targets affected tissues directly while minimizing systemic exposure and side effects. |
Earnings
Latest Release
May 14, 2026
EPS / Forecast
-0.24 / -111.59
Revenue / Forecast
-- / --
Compare BNTC to Peers and Sector
Metrics to compare | BNTC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBNTCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.8x | −1.5x | −0.4x | |
PEG Ratio | −0.99 | −0.03 | 0.00 | |
Price/Book | 2.5x | 1.9x | 2.6x | |
Price / LTM Sales | - | 66.8x | 3.0x | |
Upside (Analyst Target) | 93.1% | 157.6% | 51.8% | |
Fair Value Upside | Unlock | 1.7% | 7.2% | Unlock |
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Benitec Biopharma ADR (BNTC) Stock Price Today?
The Benitec Biopharma ADR stock price today is 13.060 USD.
What Stock Exchange Does Benitec Biopharma ADR Trade On?
Benitec Biopharma ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Benitec Biopharma ADR?
The stock symbol for Benitec Biopharma ADR is "BNTC."
What Is the Benitec Biopharma ADR Market Cap?
As of today, Benitec Biopharma ADR market cap is 435.960M USD.
What Is Benitec Biopharma ADR's Earnings Per Share (TTM)?
The Benitec Biopharma ADR EPS (TTM) is -0.934.
From a Technical Analysis Perspective, Is BNTC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Benitec Biopharma ADR Stock Split?
Benitec Biopharma ADR has split 9 times.
How Many Employees Does Benitec Biopharma ADR Have?
Benitec Biopharma ADR has 19 employees.
What is the current trading status of Benitec Biopharma ADR (BNTC)?
As of Aug 06, 2026, Benitec Biopharma ADR (BNTC) is trading at a price of 13.060 USD, with a previous close of 12.690 USD. The stock has fluctuated within a day range of 12.710 USD to 13.325 USD, while its 52-week range spans from 9.850 USD to 16.760 USD.
What Is Benitec Biopharma ADR (BNTC) Price Target According to Analysts?
The average 12-month price target for Benitec Biopharma ADR is 24.167 USD, with a high estimate of 32 USD and a low estimate of 16 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +85.04% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.